32 / 61
OAK: OS in the ITT population
Barlesi, et al. ESMO 2016 (Abs. LBA44)
9.6
13.8
HR=0.73
(95% CI 0.62–0.87)
p=0.0003
Atezolizumab (n=425)
Docetaxel (n=425)
1.0
0.8
0.6
0.4
0.2
0
0
OS estimate
27
6
3
9
18
24
21
15
12
Time (months)
Minimum follow-up 19 months